CLEVELAND, Dec. 3, 2014 /PRNewswire/
-- DATATRAK International, Inc. (OTCQX: DTRK),
the leader in developing cloud-based, unified
eClinical® technologies for the clinical trials
industry, today announced a multi-year global Enterprise Agreement
with a Top 5 CRO. The contract includes independent trial
design and use of DATATRAK ONE® Unified
Experience™ eClinical solutions for Late Phase studies.
"We continue to see growth in demand for our solutions and
services across all trial phases," said Laurence P. Birch, Chairman and CEO,
DATATRAK. "With our newest Enterprise Agreement
CRO partner the focus is on late phase trials. Partnering with
this global CRO will expand awareness of how DATATRAK
uniquely addresses the evolving needs of late phase trials
including ease of use, configurability, advanced reporting and
flexible pricing."
DATATRAK is a worldwide technology and consulting company
delivering eClinical solutions and related services for the
clinical trials industry. The company delivers a portfolio of
software solutions through the unified eClinical®
platform, safely accelerating clinical research, from Concept to
Cure®.
Join DATATRAK Thought Leaders:
- Twitter
- LinkedIn
- SlideShare
- The DATATRAK
Blog
Tweet: Top 5 CRO enters global multi-year Enterprise
Agreement for late phase #eClinical solutions
http://bit.ly/1vNrybk
About
DATATRAK International,
Inc.
DATATRAK International is a worldwide
technology and services company delivering unified
eClinical® solutions and related services for the
clinical trials industry. DATATRAK built its
multi-component, comprehensive solution on a single, unified
platform and expanded this concept to include services delivery via
DATATRAK's Clinical and Consulting Services group.
The Company delivers a complete portfolio of software products
designed to accelerate the reporting of clinical research data from
sites to sponsors and ultimately regulatory authorities, faster and
more efficiently than loosely integrated technologies. The
DATATRAK ONE® software solution, deployed
worldwide through an ASP or Enterprise Transfer offering, supports
Preclinical and Phase I - Phase IV drug and device studies in
multiple languages throughout the world. DATATRAK is
located in Cleveland, Ohio;
Bryan, Texas; Cary (RTP),
North Carolina, Chicago, Illinois; and London, England. For more information,
visit http://www.datatrak.com.
Except for the historical information contained in this press
release, the statements made in this release are forward-looking
statements. These forward-looking statements
are made based on management's expectations, assumptions, estimates
and current beliefs concerning the operations, future results and
prospects of the Company and are subject to uncertainties and
factors which are difficult to predict and, in many instances, are
beyond the control of the Company, and which could cause actual
results to differ materially from those contemplated in these
forward-looking statements. For a list of certain factors that may
cause actual results to differ materially from those contemplated
in these forward looking statements, please see the Company's
report filed with the OTCQX Market on November 13, 2014 announcing its results for the
third quarter 2014. The Company undertakes no obligation to update
publicly or revise any forward-looking statement whether as a
result of new information, future events or otherwise.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/datatrak-and-top-5-cro-enact-multi-year-enterprise-agreement-300004285.html
SOURCE DATATRAK International, Inc.